-

Nexus Pharmaceuticals, Inc. Receives Successful FDA Inspection of Pharmaceutical Manufacturing Facility in Pleasant Prairie, Wisconsin

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, Inc., a leading sterile manufacturer in the pharmaceutical industry, today announced that its pharmaceutical manufacturing facility in Pleasant Prairie, Wisconsin, was successfully inspected by the Food and Drug Administration (FDA), which will allow Nexus to begin commercial operations.

The Pleasant Prairie facility, which spans more than 84,000 square feet, is equipped with state-of-the-art isolator technology and adheres to the highest current good manufacturing practice (CGMP) standards. The facility will produce a wide array of injectable medications, providing hospitals and clinicians access to safe, affordable, and critical-need medications.

"We are thrilled to receive the EIR for our Pleasant Prairie facility," said Usman Ahmed, President & Chief Executive Officer of Nexus Pharmaceuticals. "This is a major milestone for our company and reflects our commitments to reshoring sterile pharmaceutical manufacturing to the U.S. Looking ahead, we are now in an even stronger position to accelerate growth and drive innovation in our industry.”

The rigorous FDA approval process ensures that facilities meet strict safety and quality standards. Nexus Pharmaceuticals, Inc. plans to manufacture a number of NDAs and ANDAs from the Wisconsin-based facility to bring innovative products as well as supply chain durability to the U.S. healthcare system. The leadership, regulatory, and business functions will remain in the Illinois headquarters facility.

Ahmed continued, "We are proud of our team's hard work and focus on achieving a successful inspection. This accomplishment is a testament to the expertise and dedication of our employees and our commitment to providing the highest quality medication to our customers."

For more information about the state-of-the-art manufacturing facility, visit https://www.nexuspharma.net/our-facility.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art manufacturing facility in Wisconsin, visit https://www.nexuspharma.net/project-tomorrow/.

Contacts

Deana Mndrucic
dmndrucic@nexuspharma.net
847-996-3790

More News From Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals Launches Baclofen Injection Refill Kit

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of their Baclofen Injection Refill Kit. Nexus’ kit will be the only one on the market that offers a vial presentation. “We are proud to be supplying healthcare systems with not only a life-changing drug, such as Baclofen, but also with a convenience kit to deliver the medication in a safe, accommodating, and timely fashion,” says Omair Ahmed, Chief Operating Officer at Nexus. “This kit will ease the lives of th...

Nexus Pharmaceuticals Launches Fluorescein 2 mL

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhancing the availability of Fluorescein across the optometry market. Fluorescein 2 mL and 5 mL are available in cartons of ten. Order your supply of 2 mL Fluorescein Injection, USP 25% directly through your Wholesalers or from Customer Service at (888...

Nexus Pharmaceuticals Launches Tranexamic Acid

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announced the launch of Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most. “We are very excited to be adding Tranexamic Acid to our product portfolio,” says Vince LoPiccolo, Vice President of Sales at Nexus. “Antifibrinolytic Agents, such as Tranexamic Acid, are crucial to have available in operating rooms and we are proud to contribute to the supply...
Back to Newsroom